MA44251A - Procédés comprenant un dosage intermittent et fixe de cediranib - Google Patents

Procédés comprenant un dosage intermittent et fixe de cediranib

Info

Publication number
MA44251A
MA44251A MA044251A MA44251A MA44251A MA 44251 A MA44251 A MA 44251A MA 044251 A MA044251 A MA 044251A MA 44251 A MA44251 A MA 44251A MA 44251 A MA44251 A MA 44251A
Authority
MA
Morocco
Prior art keywords
cediranib
intermittent
processes including
fixed dosage
dosage
Prior art date
Application number
MA044251A
Other languages
English (en)
French (fr)
Inventor
Simon Barry
Tony Ho
Susan Percy Ivy
Jane Kendrew
Elise Kohn
Jung-Min Lee
Stephen Robert Wedge
Original Assignee
Astrazeneca Ab
The Us Secretery Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, The Us Secretery Department Of Health And Human Services filed Critical Astrazeneca Ab
Publication of MA44251A publication Critical patent/MA44251A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA044251A 2016-02-15 2017-02-14 Procédés comprenant un dosage intermittent et fixe de cediranib MA44251A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662295421P 2016-02-15 2016-02-15

Publications (1)

Publication Number Publication Date
MA44251A true MA44251A (fr) 2018-12-26

Family

ID=59625551

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044251A MA44251A (fr) 2016-02-15 2017-02-14 Procédés comprenant un dosage intermittent et fixe de cediranib

Country Status (16)

Country Link
US (1) US20210322415A1 (https=)
EP (2) EP3417294B8 (https=)
JP (2) JP6865762B2 (https=)
KR (1) KR102830910B1 (https=)
CN (1) CN109073650A (https=)
AU (1) AU2017221268B2 (https=)
CA (1) CA3014674C (https=)
DK (1) DK3417294T3 (https=)
ES (1) ES2906813T3 (https=)
HU (1) HUE058114T2 (https=)
MA (1) MA44251A (https=)
MX (2) MX2018009867A (https=)
PL (1) PL3417294T3 (https=)
RU (1) RU2740849C2 (https=)
TW (1) TWI827530B (https=)
WO (1) WO2017142871A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI879716B (zh) 2017-05-09 2025-04-11 美商提薩羅有限公司 治療癌症的組合療法
AU2018270112A1 (en) 2017-05-18 2019-12-12 Tesaro, Inc. Combination therapies for treating cancer
EP3697442A4 (en) 2017-09-30 2021-07-07 Tesaro, Inc. COMBINATION THERAPIES FOR TREATMENT OF CANCER
SG11202002499TA (en) * 2017-10-06 2020-04-29 Tesaro Inc Combination therapies and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
SK288365B6 (sk) 1999-02-10 2016-07-01 Astrazeneca Ab Medziprodukty pre chinazolínové deriváty ako inhibítory angiogenézy
NZ522074A (en) 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
CN1255392C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管生成抑制剂的秋水仙醇衍生物
CN100566711C (zh) * 2002-04-15 2009-12-09 斯隆-凯特林癌症研究院 治疗癌症的化合物及其用途
GB0330002D0 (en) 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
WO2006035203A1 (en) * 2004-09-27 2006-04-06 Astrazeneca Ab Cancer combination therapy comprising azd2171 and imatinib
US20090035317A1 (en) * 2007-01-12 2009-02-05 Daugherty Patrick S Peptides binding to vascular endothelial growth factor
WO2009104019A1 (en) * 2008-02-21 2009-08-27 Astrazeneca Ab Combination therapy 238
US20120130144A1 (en) * 2009-02-04 2012-05-24 Bipar Sciences, Inc. Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
CA2854926A1 (en) * 2011-11-08 2013-05-16 Intellikine, Llc Treatment regimens using multiple pharmaceutical agents
TWI619704B (zh) * 2012-05-18 2018-04-01 大日本住友製藥股份有限公司 羧酸化合物
CA2889182A1 (en) * 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
EP3082853A2 (en) * 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
NO2714752T3 (https=) * 2014-05-08 2018-04-21
TWI716362B (zh) * 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途

Also Published As

Publication number Publication date
KR20180125456A (ko) 2018-11-23
JP6865762B2 (ja) 2021-04-28
EP3417294B1 (en) 2021-12-01
JP2021105039A (ja) 2021-07-26
PL3417294T3 (pl) 2022-05-09
JP2019504860A (ja) 2019-02-21
ES2906813T3 (es) 2022-04-20
AU2017221268B2 (en) 2024-02-15
MX2023007826A (es) 2023-07-07
HUE058114T2 (hu) 2022-07-28
TWI827530B (zh) 2024-01-01
RU2018131377A3 (https=) 2020-06-02
AU2017221268A1 (en) 2018-08-30
US20210322415A1 (en) 2021-10-21
EP3417294A4 (en) 2019-08-14
RU2740849C2 (ru) 2021-01-21
CA3014674A1 (en) 2017-08-24
TW201906610A (zh) 2019-02-16
EP3417294A1 (en) 2018-12-26
EP4071174A1 (en) 2022-10-12
CA3014674C (en) 2024-06-18
KR102830910B1 (ko) 2025-07-04
MX2018009867A (es) 2019-05-27
WO2017142871A1 (en) 2017-08-24
WO2017142871A8 (en) 2018-06-14
RU2018131377A (ru) 2020-03-17
CN109073650A (zh) 2018-12-21
JP7271594B2 (ja) 2023-05-11
EP3417294B8 (en) 2022-05-04
DK3417294T3 (da) 2022-02-21

Similar Documents

Publication Publication Date Title
IL259299B (en) System for determining the health and gender of a chick
EP3720549A4 (en) PATIENT THERAPY SYSTEMS AND METHODS
EP3586113A4 (en) BIOMIMETIC SENSOR PLATFORM UNIT
EP3262407C0 (en) PARTITION PROCESSING METHODS AND SYSTEMS
DK3485237T3 (da) Dosismålesystemer
IL256145B (en) Systems and methods for patient-specific dosing
EP3258883A4 (en) DEVICE, SYSTEMS AND METHOD FOR HEART TREATMENT
EP3303413A4 (en) PROCESS FOR THE PREPARATION OF SUGAMMADEX AND INTERMEDIATE PRODUCTS THEREOF
EP3367987A4 (en) DEVICE AND METHOD FOR WOUND THERAPY
EP4098297C0 (en) DEVICE FOR OBTAINING DOSES FOR SYRINGES
EP3380837A4 (en) TEST DEVICE
IL253612B (en) Delivery of hydrophobic active agent particles
EP3307772A4 (en) TGF-BETA-3 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
EP3323516A4 (en) COATING METHOD AND COATING DEVICE
EP3538071A4 (en) PHARMACEUTICAL COMPOUNDING METHODS AND SYSTEMS
EP3454924A4 (en) RADIOLOGICAL DOSING SYSTEM AND METHOD
DK3701944T3 (da) Oro-dispergerbar doseringsenhed indeholdende en estetrolkomponent
EP3727179A4 (en) DISINFECTING PROCEDURE AND DEVICE
EP3402540C0 (en) STERILIZATION DEVICE AND METHOD
IL272934A (en) Pharmaceutical compositions containing a high dose of pridopidine
DK3310340T3 (da) Formulering med høj koncentration
EP3606465A4 (en) Dosing regimens and related compositions and methods
EP3370064A4 (en) REAGENT AND METHOD FOR MEASURING A THROMBIN ANTITHROMBIN COMPLEX
FR3026303B1 (fr) Procede de sechage de dispositif medical
EP3678089A4 (en) DRUG INSPECTION DEVICE, IMAGE PROCESSING DEVICE, IMAGE PROCESSING PROCESS AND PROGRAM